Adynxx is a biopharmaceutical company focused on bringing to market disease-modifying products for the treatment of pain and inflammation. It works to discover and develop transcription factor decoys to modify the course of pain, to collaborate with discovery partners, and to identify in-licensing opportunities with transformative therapeutic profiles to build a pipeline in pain and inflammation.